{"classes":[{"categories":[{"measurements":[{"comment":"week 0 pre-dose serum concentrations are below the level of detection","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"week 0 pre-dose serum concentrations are below the level of detection","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"339"}],"units":"Participants"}],"title":"Week 0 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"338","value":"511"},{"groupId":"OG001","spread":"162","value":"484"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"334"}],"units":"Participants"}],"title":"Week 0 - Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.4","value":"75.3"},{"groupId":"OG001","spread":"56.5","value":"78.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"title":"Week 4 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"97.7","value":"125"},{"groupId":"OG001","spread":"82.5","value":"144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"title":"Week 12 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"298","value":"594"},{"groupId":"OG001","spread":"233","value":"576"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"186"}],"units":"Participants"}],"title":"Week 12 - Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.4","value":"150"},{"groupId":"OG001","spread":"82.5","value":"163"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"Week 24 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"249","value":"604"},{"groupId":"OG001","spread":"244","value":"600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Week 24 - Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50","value":"23.3"},{"groupId":"OG001","spread":"18.4","value":"19.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"Follow-up Month 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"description":"Blood samples were collected to determine the serum concentration of durvalumab.","dispersionType":"Standard Deviation","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included all patients who received at least 1 dose of durvalumab or tremelimumab per the protocol and had at least one post dose evaluable PK data of durvalumab or tremelimumab","reportingStatus":"POSTED","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.","title":"Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set","type":"SECONDARY","unitOfMeasure":"μg/mL"}